EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

Shijun Cao, Changxin Zhong, Shilong Jiang, Yungui Li, Yang Xi, Mingxuan Xiao, Ting Jiang, Xiaoya Wan, Zonglin Chen, Xiaohui Yu, Yan Cheng iD

Advanced Science · 2026

DOI: 10.1002/advs.202520863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Shijun Cao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University /Hunan Cancer Hospital, Changsha, Hun…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Elongation Factor 2 Kinase, Proteolysis Targeting Chimera, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Innovation Program of Hunan Province, Talent Project Established by Chinese Pharmaceutical Association Hospital Pharmacy Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis‐targeting chimera (PROTAC) have emerged as a promising class of anticancer agents. Eukaryotic elongation factor 2 kinase (eEF2K), a stress‐responsive regulator of translational elongation, has emerged as a pivotal therapeutic target in triple‐negative breast cancer (TNBC) due to its critical role in sustaining cancer cell survival under nutrient stress. Building on our previous work identifying eEF2K as an oncogenic kinase, this study developed an eEF2K‐targeting PROTAC that exhibited potent antitumor activity against TNBC. Through a structure‐guided design, we identified a key allosteric pocket of eEF2K and linked its inhibitor 2S to a CRBN ligand to generate A6, a PROTAC that promotes eEF2K degradation via a conformationally optimized interface, achieving >90% target depletion while preserving the total levels of its substrate eEF2. A6 exhibited anti‐proliferative effects across TNBC cell lines by degrading eEF2K. In Vivo and in TNBC organoid models, A6 treatment significantly suppressed tumor growth, with favorable tolerability. To further enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier that promotes drug accumulation at tumor sites compared to free A6, leading to improved therapeutic outcomes. Collectively, our data indicate that targeted degradation of eEF2K via PROTAC technology constitutes a novel and therapeutically relevant intervention strategy for TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsElongation Factor 2 KinaseProteolysis Targeting ChimeraAntineoplastic AgentsHumansFemaleAnimalsMiceCell Line, TumorProteolysis

Stichwörter der Autor:innen

A6A6@ZIF‐8PROTACTriple‐negative breast cancereEF2K

Substanzen

Elongation Factor 2 KinaseProteolysis Targeting ChimeraEEF2K protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pathology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University /Hunan Cancer Hospital, Changsha, Hunan, China.
  • Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, Hunan, China.
  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • The Hunan Institute of Pharmacy Practice and Clinical Research, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

ORCID-Profile: Yan Cheng

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Innovation Program of Hunan Province
  • Talent Project Established by Chinese Pharmaceutical Association Hospital Pharmacy Department

Zitieren

APA

Cao, S., Zhong, C., Jiang, S., Li, Y., Xi, Y., Xiao, M., Jiang, T., Wan, X., Chen, Z., Yu, X., & Cheng, Y. (2026). Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202520863

Vancouver

Cao S, Zhong C, Jiang S, Li Y, Xi Y, Xiao M, et al. Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer. Advanced Science. 2026. doi:10.1002/advs.202520863

BibTeX
@article{Cao2026,
  author = {Cao, Shijun and Zhong, Changxin and Jiang, Shilong and Li, Yungui and Xi, Yang and Xiao, Mingxuan and Jiang, Ting and Wan, Xiaoya and Chen, Zonglin and Yu, Xiaohui and Cheng, Yan},
  title = {Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202520863}
}
Kostenlos starten →